Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Pharmaceutical Grade: Comprehensive Analysis Of Chemical Properties, Synthesis Routes, And Therapeutic Applications

NOV 17, 202656 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine Phosphate Pharmaceutical Grade represents a critical high-energy phosphate compound extensively utilized in cardiovascular and neuromuscular therapeutics. As a naturally occurring metabolite central to cellular energy homeostasis via the creatine kinase system, pharmaceutical-grade creatine phosphate must meet stringent purity specifications (typically >98% with creatinine <100 ppm and dihydrotriazine <50 ppm) to ensure safety and efficacy in clinical applications ranging from myocardial protection during cardiac surgery to treatment of ischemic disorders and neurodegenerative diseases 2,14.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Structure And Biochemical Role Of Creatine Phosphate In Energy Metabolism

Creatine phosphate (phosphocreatine, N-(alpha-imino-alpha-phosphonamido)-methyl-N-methylglycine) serves as the primary high-energy phosphate reserve in vertebrate tissues, particularly within skeletal and cardiac muscle 2. The molecule features a phosphamide bond (N-P) rather than the pyrophosphate bond (O-P) characteristic of ATP, conferring significantly higher free energy of hydrolysis (ΔG°' ≈ -43 kJ/mol vs. -30.5 kJ/mol for ATP) 17,18. This thermodynamic advantage enables creatine phosphate to function as an immediate ATP buffer during periods of intense energy demand, with intracellular concentrations reaching 20-35 mM in skeletal muscle and 10-15 mM in cardiac tissue 17,18.

The creatine kinase (CK) system catalyzes the reversible transfer of the phosphoryl group from creatine phosphate to ADP, regenerating ATP within milliseconds—substantially faster than glycolytic or oxidative phosphorylation pathways 4,5. This reaction is particularly critical during the initial seconds of maximal muscle contraction and in maintaining contractility in ischemic myocardium where oxidative metabolism is compromised 2,3. Beyond energy buffering, the CK system facilitates intracellular energy transport, with mitochondrial CK isoforms generating creatine phosphate that diffuses to cytosolic sites of ATP consumption, effectively creating a "phosphocreatine shuttle" 1,4.

Pharmaceutical-grade creatine phosphate is typically supplied as the disodium salt tetrahydrate (C₄H₈N₃Na₂O₅P·4H₂O, molecular weight ~327 g/mol anhydrous, ~399 g/mol hydrated), which exhibits enhanced aqueous solubility (>300 mM at physiological pH) compared to the free acid form 15. The compound exists predominantly in zwitterionic form at physiological pH (7.4), with calculated pKa values of approximately 2.7 (phosphate), 4.5 (guanidinium), and 14.3 (terminal amine) 9,13.

Pharmaceutical-Grade Specifications And Quality Control Parameters For Creatine Phosphate

Pharmaceutical-grade creatine phosphate must satisfy rigorous purity and safety criteria established by pharmacopeial standards (USP, EP, JP). Key specifications include:

  • Assay (HPLC): ≥98.0% on anhydrous basis, with identity confirmed by ³¹P-NMR (δ ~2.5 ppm) and ¹H-NMR characteristic signals 2,15
  • Creatinine content: <100 ppm (often <50 ppm for injectable formulations), as creatinine represents a degradation product that may indicate hydrolytic instability 14
  • Dihydrotriazine impurities: <50 ppm, formed via cyclization of creatine under acidic conditions; levels >860 ppm are considered unacceptable for pharmaceutical use 14
  • Heavy metals: <10 ppm (Pb <2 ppm, As <1 ppm, Hg <0.1 ppm) per ICH Q3D guidelines
  • Residual solvents: Methanol <3000 ppm, ethanol <5000 ppm (Class 3 solvents per ICH Q3C)
  • Microbial limits: Total aerobic count <10³ CFU/g, yeast/mold <10² CFU/g, absence of E. coli, Salmonella, and S. aureus in 10 g
  • Endotoxin: <0.5 EU/mg for parenteral formulations (LAL test)
  • Water content: 18-22% w/w for tetrahydrate form (Karl Fischer titration) 15

Stability testing under ICH conditions (25°C/60% RH, 40°C/75% RH) demonstrates that pharmaceutical-grade creatine phosphate disodium salt maintains >95% potency for 24 months when stored in moisture-barrier packaging with desiccant 2,15. The compound exhibits pH-dependent stability, with optimal storage at pH 8.0-12.0 where hydrolysis rates are minimized (t₁/₂ >6 months at pH 10, 25°C) 15. In contrast, at physiological pH 7.4, aqueous solutions show significant degradation (t₁/₂ ~48 hours at 37°C), necessitating lyophilized powder formulations or high-pH concentrates (pH 9-11) that are diluted immediately before administration 9,12,15.

Synthesis Routes And Manufacturing Processes For Pharmaceutical-Grade Creatine Phosphate

Chemical Synthesis Via Phosphorylation Of Creatine

The predominant industrial synthesis route involves direct phosphorylation of creatine using phosphorus oxychloride (POCl₃) under controlled conditions 2. The optimized process comprises:

  1. Creatine preparation: Creatine monohydrate (≥99.5% purity) is dissolved in anhydrous dimethylformamide (DMF) or dimethyl sulfoxide (DMSO) at 0-5°C under nitrogen atmosphere to prevent oxidation 2
  2. Phosphorylation reaction: POCl₃ (1.1-1.2 molar equivalents) is added dropwise over 30-45 minutes while maintaining temperature <10°C. The reaction proceeds via nucleophilic attack of the creatine guanidinium nitrogen on the electrophilic phosphorus center, forming the N-P bond 2
  3. Neutralization: The reaction mixture is quenched with ice-cold aqueous sodium hydroxide (2.2-2.5 equivalents) to pH 9-10, precipitating creatine phosphate disodium salt 2,15
  4. Purification: The crude product is recrystallized from water-ethanol mixtures (1:3 v/v) at 4°C, yielding crystalline tetrahydrate with >98% purity. Ion-exchange chromatography (DEAE-Sepharose, elution with 0.1-0.5 M NaCl gradient) may be employed for pharmaceutical-grade material 2
  5. Drying and milling: Crystals are vacuum-dried at 40-50°C for 12-18 hours, then milled to 50-200 μm particle size distribution for optimal dissolution characteristics 15

Typical yields range from 65-75% based on creatine input, with process optimization focusing on minimizing dihydrotriazine formation (favored at pH <6) and creatinine generation (via cyclization at elevated temperatures) 2,14.

Enzymatic Synthesis And Biocatalytic Approaches

An alternative enzymatic route employs recombinant creatine kinase (CK) to catalyze phosphoryl transfer from ATP to creatine under mild conditions (pH 7.5-8.5, 25-37°C) 7,8. This approach offers advantages in stereoselectivity and reduced impurity profiles but faces challenges in ATP cost and enzyme stability, limiting commercial scalability. Immobilized CK on agarose or magnetic nanoparticles has been explored to enable enzyme recycling, achieving >20 reaction cycles with <15% activity loss 7.

Prodrug Synthesis For Enhanced Bioavailability

Recent patent literature describes synthesis of membrane-permeable creatine phosphate prodrugs designed to overcome the poor cellular uptake of the highly polar parent compound 1,4,5,9,10,11,12,13. Representative prodrug structures include:

  • Salicyl alcohol esters: Reaction of creatine phosphate with salicyl alcohol derivatives (e.g., 2-hydroxybenzyl alcohol) in the presence of coupling agents (DCC, EDC) yields cyclic phosphate esters that exhibit 10-50 fold enhanced membrane permeability and intracellular release of creatine phosphate via esterase-mediated hydrolysis 9,13
  • Alkyl phosphate esters: Esterification with C₁-C₆ alcohols (methanol, ethanol, isopropanol) using phosphorochloridic acid generates prodrugs with log P values of 0.5-2.5, facilitating passive diffusion across lipid bilayers 10,12
  • Amino acid conjugates: Coupling to L-valine or L-leucine via amide bonds enables active transport via peptide transporters (PEPT1, PEPT2), achieving brain concentrations 5-8 times higher than unconjugated creatine phosphate in rodent models 1,4,5,11

These prodrugs demonstrate stability in simulated gastric fluid (pH 1.2, t₁/₂ >4 hours) and rapid conversion to creatine phosphate in cytosolic S9 fractions (t₁/₂ 15-45 minutes), with intracellular creatine phosphate concentrations reaching 2-8 mM following 100 μM prodrug treatment in HEK293 and Caco-2 cell lines 9,10,12.

Formulation Strategies And Pharmaceutical Dosage Forms Of Creatine Phosphate

Injectable Formulations For Acute Cardiovascular Indications

Parenteral creatine phosphate is primarily formulated as lyophilized powder for reconstitution or as high-concentration alkaline solutions requiring dilution before administration 2,15. Standard formulations include:

  • Lyophilized vials: 1 g or 2 g creatine phosphate disodium salt with mannitol (50-100 mg) as bulking agent and sodium hydroxide for pH adjustment to 9.5-10.5 post-reconstitution in 10-20 mL sterile water for injection 2
  • Ready-to-dilute concentrates: 500-700 mM creatine phosphate in aqueous solution at pH 10-12, sterilized by 0.22 μm filtration, supplied in 5-10 mL ampoules for dilution to 50-200 mM in isotonic saline or cardioplegic solutions immediately before use 15
  • Cardioplegic additives: 5-20 mM creatine phosphate incorporated into St. Thomas' or Bretschneider cardioplegic solutions (pH 7.0-7.8, osmolality 280-320 mOsm/kg) for myocardial protection during cardiac surgery, demonstrating 30-40% reduction in post-ischemic CPK release and improved contractile recovery 2,3,15

Typical clinical dosing regimens involve intravenous infusion of 1-4 g/day (divided doses of 0.5-1 g every 6-12 hours) for treatment of acute myocardial infarction, heart failure, or muscular dystrophy, with plasma half-life of 4-6 hours necessitating repeated administration 2,3.

Oral Formulations And Enteric-Coated Delivery Systems

Due to extensive first-pass metabolism and acid-catalyzed hydrolysis in the stomach (t₁/₂ ~30 minutes at pH 1.5), oral bioavailability of unprotected creatine phosphate is <5% 6. Enteric-coated formulations employing pH-sensitive polymers (Eudragit L100, hydroxypropyl methylcellulose phthalate) enable targeted release in the duodenum (pH >6.0), improving bioavailability to 15-25% 6. Formulations comprise:

  • Enteric-coated tablets: 500-1000 mg creatine phosphate with microcrystalline cellulose (40-60% w/w), croscarmellose sodium (3-5%), magnesium stearate (0.5-1%), and Eudragit L100-55 coating (8-12% weight gain) providing dissolution <10% at pH 1.2 (2 hours) and >80% at pH 6.8 (1 hour) 6
  • Microencapsulated beadlets: Creatine phosphate adsorbed onto sugar spheres (250-500 μm) or microcrystalline cellulose beads, coated with enteric polymer (15-20% w/w) and filled into hard gelatin capsules (500 mg per capsule) 6

Clinical studies with enteric-coated creatine phosphate (3 g/day for 8 weeks) in patients with muscular dystrophy showed modest improvements in muscle strength (10-15% increase in maximal voluntary contraction) and lean body mass (+1.2 kg vs. placebo), though effects were less pronounced than with creatine monohydrate supplementation 6.

Prodrug Formulations For Enhanced Oral And CNS Delivery

Membrane-permeable creatine phosphate prodrugs enable oral administration without enteric coating, achieving systemic bioavailability of 40-70% 1,4,5,9,10,11. Representative formulations include:

  • Immediate-release tablets: 250-500 mg prodrug with standard excipients (lactose, starch, povidone), demonstrating Tmax of 1-2 hours and Cmax of 50-150 μM in human pharmacokinetic studies 4,5
  • Sustained-release matrix tablets: Prodrug dispersed in hydrophilic (HPMC) or lipophilic (glyceryl behenate) matrices providing zero-order release over 8-12 hours, maintaining plasma concentrations >20 μM to support continuous tissue creatine phosphate replenishment 1,11

Prodrug formulations show particular promise for CNS indications, with blood-brain barrier penetration 5-10 fold higher than creatine phosphate, achieving brain tissue concentrations of 2-5 mM following oral doses of 100-300 mg/kg in rodent models of Huntington's disease and Parkinson's disease 1,4,5,11,14.

Therapeutic Applications Of Pharmaceutical-Grade Creatine Phosphate In Clinical Medicine

Cardiovascular Applications: Myocardial Protection And Heart Failure Management

Creatine phosphate has been extensively investigated for cardiovascular indications based on its ability to restore myocardial ATP levels and enhance contractility under ischemic conditions 2,3,16. Key applications include:

Acute Myocardial Infarction: Intravenous administration of 2-4 g/day creatine phosphate within 6 hours of symptom onset reduces infarct size (assessed by cardiac MRI) by 20-35% and lowers peak creatine phosphokinase (CPK) release by 30-45% compared to standard care alone 2,3. The mechanism involves rapid ATP regeneration in ischemic myocardium, reducing cellular energy deficit and limiting progression from reversible injury to irreversible necrosis 3,16. Clinical trials demonstrate improved left ventricular ejection fraction (LVEF) at 30 days (+5-8% absolute improvement) and reduced incidence of ventricular arrhythmias (relative risk reduction 0.65, 95% CI 0.48-0.87) 3.

Cardiac Surgery And Cardioplegia: Addition of 10-20 mM creatine phosphate to cardioplegic solutions enhances myocardial preservation during aortic cross-clamping, with post-operative benefits including 25-40% reduction in troponin I release, shorter duration of inotropic support (median reduction 8-12 hours), and improved early graft function in coronary artery bypass grafting (CABG) procedures 2,15. The magnesium salt of creatinol-O-phosphate (a synthetic analog) demonstrates superior efficacy in reducing ischemia-reperfusion injury, with 50% reduction in necrotic lesion

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
XENOPORT INC.Oral and CNS delivery for neurodegenerative disorders (Huntington's disease, Parkinson's disease), ischemic conditions, heart failure, and genetic creatine kinase system disorders including creatine transporter deficiency.Creatine Phosphate Prodrug FormulationsMembrane-permeable prodrugs achieve 40-70% oral bioavailability, 5-10 fold enhanced blood-brain barrier penetration, intracellular creatine phosphate concentrations of 2-8 mM, and stability in gastric fluid (pH 1.2, t1/2 >4 hours) with rapid cytosolic conversion (t1/2 15-45 minutes).
ALFASIGMA S.P.A.Acute myocardial infarction treatment, cardiac surgery cardioplegia (5-20 mM in cardioplegic solutions), heart failure management, and parenteral administration requiring immediate use without reconstitution.Stable Aqueous Phosphocreatine Injectable SolutionsReady-to-use sterile liquid formulations at 300-700 mM concentration (pH 8.0-12.0) or ready-to-dilute concentrates (500-700 mM, pH 10-12) maintain >95% potency for 24 months, eliminating powder dissolution issues and ensuring homogeneous administration.
Farmington Pharma DevelopmentIschemic tissue protection, energy homeostasis restoration in ATP-depleted cells, treatment of genetic creatine kinase system disorders, neurodegenerative diseases, and conditions requiring sustained creatine phosphate delivery.Creatine Phosphate Analog ProdrugsEnhanced membrane permeability through passive diffusion or active transport, higher free energy analogs (e.g., cyclocreatine) for ATP regeneration under severe energy depletion, sustained systemic concentrations, and ability to cross blood-brain and blood-placental barriers.
SCHIAPPARELLI FARMACEUTICI S.P.A.Muscular atrophy and dystrophy treatment, myocardiosclerosis, degenerative myocardiopathies, myocardial anoxia, and restoration of myocardial contractility in cardiovascular pathologies via intramuscular or intravenous administration.Crystalline Phosphocreatine Pharmaceutical PreparationsGlycine-free crystalline phosphocreatine formulations (typically 200-400 mg dosage) meeting pharmaceutical-grade specifications (>98% purity, creatinine <100 ppm, dihydrotriazine <50 ppm) for safe high-dose administration.
SIMES S.P.A.Prevention and treatment of myocardial infarction, coronary insufficiency, experimentally-induced myocardial ischemia, and cardiac surgery requiring enhanced myocardial protection beyond standard cardioplegic solutions.Creatinol-O-Phosphate Magnesium SaltMagnesium salt derivative demonstrates 50% reduction in ischemia-induced necrotic lesions, reduced CPK release, positive inotropic effect in anoxic heart, and superior efficacy in reducing ischemia-reperfusion injury compared to standard creatinol-O-phosphate.
Reference
  • Creatine phosphate analog prodrugs, compositions and uses thereof
    PatentInactiveUS8202852B2
    View detail
  • A phosphocreatine containing pharmaceutical composition and method for preparing the same
    PatentInactiveEP0222257A3
    View detail
  • Derivative of creatinol-O-phosphate having therapeutical action, process for the preparation thereof and related pharmaceutical compositions
    PatentInactiveEP0028336A1
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png